Product Description
ABBV-2222 (formerly GLPG2222) is a type of CFTR modulator called a corrector. (Sourced from: )
Mechanisms of Action: CFTR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Galapagos
Company Location: 2800 MECHELEN C9 00000
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Cystic Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07035990 |
SION-451-101 | P1 |
Recruiting |
Cystic Fibrosis |
2026-06-01 |
2% |
2025-09-03 |